3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
50
Neoplasm Metastasis
10
Neoplasms
8
Recurrence
7
Prostate Cancer Metastatic
6
Breast Neoplasms
5
Carcinoma, Transitional Cell
4
Stomach Neoplasms
3
Neoplastic Cells, Circulating
3
Metastatic Castration-resistant Prostate Cancer
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms, Castration-Resistant
2
Ovarian Neoplasms
2
Glioblastoma
2
Carcinoma, Squamous Cell
2
Thrombocytosis
1
Testicular Neoplasms
1
Solid Cancer
1
Small Cell Lung Carcinoma
1
Prostate Cancer, Hereditary, 7
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Nonseminomatous germ cell tumor
1
Myeloproliferative Disorders
1
Interventions
Cisplatin
55
Carboplatin
50
pembrolizumab
42
Paclitaxel
42
Gemcitabine
28
Pemetrexed
23
Radiotherapy
21
Magnetic Resonance Spectroscopy
20
Radiotherapy, Intensity-Modulated
18
Docetaxel
17
Cetuximab
17
Specimen Handling
16
Nivolumab
16
Fluorouracil
16
Cyclophosphamide
14
durvalumab
13
Bevacizumab
12
Radiation
11
130-nm albumin-bound paclitaxel
11
Sorafenib
10
Platinum
10
1,2-diaminocyclohexaneplatinum II citrate
10
osimertinib
9
Sunitinib
8
Oxaliplatin
8
Irinotecan
8
Ipilimumab
8
Everolimus
8
Drug Therapy
8
Capecitabine
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma
×
cabazitaxel
×
Clear all
NCT02202772
2025-02-24
CGC
Columbia University
Phase 1/2
Active not recruiting
51 enrolled